Catena Docetaxel CAS 196404-55-4 Docetaxel puritas media >99.0% (Titration)
Shanghai Ruifu Chemical Co., Ltd. est primarius fabricae Catenae lateris Docetaxel (CAS: 196404-55-4) cum qualitate alta.Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Side Chain of Docetaxel,Please contact: alvin@ruifuchem.com
| Nomen chemicum | (4S,5R) -3-(tert-Butoxycarbonyl) -2-(4-Methoxyphenyl) -4-Phenyloxazolidine-5-Carboxylic Acidum |
| Synonyma | Catena de Docetaxel;(4S,5R) -3-tert-butoxycarbony-2-(4-anisyl)-4-Phenyl-5-Oxazolidinecarboxylic Acid;(4S,5R)-2-(4-Methoxy-phenyl)-3-N-Boc-4-Phenyl-3,5-Oxazolidinum Acidum carboxylicum |
| Stock Status | In Stock, Commercial Scale |
| CAS Number | 196404-55-4 |
| Formulae hypotheticae | C22H25NO6 |
| M. Pondus | 399.44 g/mol |
| Liquescens punctum | 127.0~ 137.0℃ |
| Density | 1.238 |
| Repono Nativ. | Frigus & siccum (2~8℃) |
| naviportans | Normal |
| COA & MSDS | Praesto |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Salus Descriptio | 24/25 - contactus cum cute et oculis fuge. |
| HS Code* | 2932999029 |
| Items | Signa inspectionis | Proventus |
| Aspectus | Alba vel Off-White Crystalline pulveris | Obsequitur |
| Liquescens punctum | 127.0~ 137.0℃ | 133.8~ 135.4℃ |
| Imprimis rotationis [α]20/D | +65.0° to +75.0° | +72.4° |
| UV | λ max 227nm | Obsequitur |
| Substantia cognata (Per HPLC) | ≤2.00% | 0.7% |
| Damnum in Siccatio | <0.50% | 0.2% |
| Puritas / Analysis Methodus | >99.0% (By Titration) | 99.4% |
| 1 H NMR Spectrum | Conformat ut Structure | Obsequitur |
| conclusio | Productum probatum est & obsequitur datis specificationibus | |
Sarcina:Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Condite in arcte clauso vase.Condite in loco frigido, sicco (2~8℃) et cellario bene ventilato ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
(4S,5R)-3-(tert-Butoxycarbonyl) -2-(4-Methoxyphenyl) -4-Phenyloxazolidine-V-Acidi Carboxylici (Cathenae Docetaxel) (CAS: 196404-55-4) est medium/impuritatem. pro Docetaxel (CAS: 114977-28-5) et Docetaxel Trihydratus (CAS: 148408-66-6).Adhiberi potest etiam ad analogias quinolino-docetaxel componendas, quae actionem anticancri exhibent.
Docetaxel taxane est, antineoplastic, et anticancer medicamentum localiter provectus vel metastaticus cancer pectoris tractabat, etiam post defectum therapiae cisplatinae.Eius efficacia anti-tumor in vitro probat ut 1.3-12 temporibus paclitaxel probatum est.Studia clinica ostenderunt efficaciorem esse quam paclitaxel contra cancrum anthracyclinum renitentem.Docetaxel in praesenti efficacissima est curationis secundae lineae anthracyclinae cancer carcinomatis repugnantis.In una therapia cellularum et chemotherapy combinata ad cancrum pulmonis non parvae cellae, unum ex medicamentis efficacissimis est.Ad cancrum uteri adhiberi potest, et ad studium antibioticos, cellam biologiam, cellulam significationis, neuroscientiam, apoptosin et cyclos cellularum.Adhibetur etiam studiosurae detrimentum capillorum per chemotherapy docetaxel causari, et ne et cancer pulmonis minuti-celluli in patientibus contraindicata chemotherapy tractat.Solet etiam inquirere partes hypoxiae-inducibiles 1α et 2α in cellulis cancer prostativis androgenis-sensibilibus.
